Media headlines about Cytori Therapeutics (NASDAQ:CYTX) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a news impact score of 0.02 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.5698965473991 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Hair-Raising Facts to Know – Cytori Therapeutics Inc (NASDAQ: CYTX) – Stock Trading Point (press release) (stocktradingpoint.com)
- Hot Stock’s Watch List – Cytori Therapeutics Inc (NASDAQ: CYTX) – Stock Trading Point (press release) (stocktradingpoint.com)
- Cytori Therapeutics, Inc. (NASDAQ:CYTX) – Analysts’ Suggestions in the Limelight – Nasdaq Journal (nasdaqjournal.com)
- Monthly Gainer – Cytori Therapeutics, Inc. (CYTX) returned -1.60% up – The Stocks News (press release) (thestocksnews.com)
- Technical Secrets – Cytori Therapeutics Inc (NASDAQ: CYTX) – Alpha Beta Stock (alphabetastock.com)
Cytori Therapeutics (CYTX) traded up $0.01 on Friday, reaching $0.32. The company’s stock had a trading volume of 127,817 shares, compared to its average volume of 1,666,676. The firm has a market capitalization of $19.12, a P/E ratio of -0.37 and a beta of 3.10. Cytori Therapeutics has a 12-month low of $0.22 and a 12-month high of $2.08.
Cytori Therapeutics (NASDAQ:CYTX) last released its earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The firm had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.00 million. Cytori Therapeutics had a negative return on equity of 210.47% and a negative net margin of 418.36%. analysts forecast that Cytori Therapeutics will post -0.18 EPS for the current year.
Several equities analysts have recently issued reports on the company. B. Riley upgraded Cytori Therapeutics from a “neutral” rating to a “buy” rating in a research report on Friday, March 9th. Maxim Group set a $2.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 9th. Zacks Investment Research downgraded Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 8th. Laidlaw restated a “buy” rating and issued a $1.65 target price on shares of Cytori Therapeutics in a research report on Thursday, February 22nd. Finally, ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $1.80.
In other Cytori Therapeutics news, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total value of $38,000.00. Following the transaction, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ag Postfinance sold 286,982 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the completion of the transaction, the insider now directly owns 5,118,627 shares in the company, valued at approximately $1,586,774.37. The disclosure for this sale can be found here. Insiders sold 695,767 shares of company stock worth $231,951 in the last ninety days. 1.90% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This story was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/23/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cytori-therapeutics-cytx-share-price.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.